Recent Quotes (30 days)

You have no recent quotes
chg | %

Silence Therapeutics plc  

(Public, LON:SLN)   Watch this stock  
Find more results forSLN
+3.00 (1.12%)
Real-time:   9:20a.m. BST
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 270.00 - 273.00
52 week 160.00 - 335.00
Open 270.00
Vol / Avg. 886.00/6,006.00
Mkt cap 188.46M*
P/E     -
Div/yield     -
EPS -0.22*
Shares 69.80M
Beta     -
Inst. own     -
Aug 13, 2015
Silence Therapeutics PLC at Canaccord Genuity Growth Conference - 4:00p.m. BST - Add to calendar
Jun 26, 2015
Silence Therapeutics PLC Annual Shareholders Meeting (Estimated)
Jun 1, 2015
Silence Therapeutics PLC Annual Shareholders Meeting
May 19, 2015
Silence Therapeutics PLC at Biocentury BioEquity Europe

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -68300.00% -73920.00%
Operating margin -80200.00% -80846.66%
EBITD margin - -78633.34%
Return on average assets -33.83% -37.54%
Return on average equity -35.80% -40.08%
Employees 51 -
CDP Score - -


1 Lyric Square/Hammersmith
United Kingdom - Map
+44-20-37009711 (Phone)
+44-7-957318494 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Silence Therapeutics plc (Silence Therapeutics) is a United Kingdom-based company engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company’s products include Atu027, which is in a phase IIa clinical trial and Atu111, which is in Phase I of pre-clinical trial stage. Atu027 is Silence’s leading short interfering RNA (siRNA) therapy. It uses the Company’s AtuPLEX and AtuRNAi technologies to deliver siRNA to the endothelial cells of the vascular system, targeting the expression of the protein PKN3, a key factor in cancer progression and metastasis.

Officers and directors

Alastair James Riddell Interim Executive Chairman of the Board
Age: 65
Timothy C. A. Freeborn Chief Financial Officer, Finance Director, Secretary, Director
Age: 54
Lars Karlsson Head of Research and Development, Executive Director
Age: 54
Michael Khan Ph.D. Chief Medical Officer, Director
Simon J. Sturge Non-Executive Director
Age: 56
Stephen B. Parker Independent Non-Executive Director
Age: 56